CClinicalTrials.gg
Sign In
Active, not recruitingNCT00445367Updated Oct 2, 2025

Biobank For MS And Other Demyelinating Diseases

An observational study in Multiple Sclerosis, Transverse Myelitis and Neuromyelitis Optica, sponsored by Accelerated Cure Project for Multiple Sclerosis. Active, not recruiting at 10 sites in United States. Per ClinicalTrials.gov, last updated 2025-10-02.

Sponsored by Accelerated Cure Project for Multiple Sclerosis · Observational

Study type
Observational
Model
Case-control
Time perspective
Other
Enrollment
3,226
Sex
All
01

Study summary

To establish a large, longitudinal collection of high quality samples and data from subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected controls. Samples and data will be available as a shared resource to scientists researching the causes, sub-types, and biomarkers of MS and related demyelinating diseases.

02

Conditions studied

  • Multiple Sclerosis
  • Transverse Myelitis
  • Neuromyelitis Optica
  • Acute Disseminated Encephalomyelitis
  • Optic Neuritis

Keywords

  • Multiple Sclerosis
  • Clinically Isolated Syndrome
  • Transverse Myelitis
  • Neuromyelitis Optica
  • Acute Disseminated Encephalomyelitis
  • Optic Neuritis
  • Repository
  • Biobank
03

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Subjects with MS, selected other demyelinating diseases (Transverse Myelitis (TM), Neuromyelitis Optica (NMO) or Devic's, Acute Disseminated Encephalomyelitis (ADEM), and Optic Neuritis (ON)), and related and unrelated unaffected controls.

Inclusion criteria

  • age 18+ able to give informed consent or individuals younger than 18 with parental permission and able to give assent
  • willing to provide up to 110 ml (50 ml for \< 18 years old) of blood via venipuncture
  • experienced at least one CNS demyelinating event characteristic of MS, TM, NMO, ADEM, or ON

Exclusion criteria

Exclusion Criteria:

  • history of blood borne pathogens
  • allogeneic bone marrow transplant
  • clinical or radiological evidence of stroke, meningitis, or other well characterized diseases of the nervous system (with the exception of MS, TM, NMO, ADEM, or ON).
  • weight less than 37 pounds
04

Study design

Observational model
Case-control
Time perspective
Other
Enrollment
3,226 participants (actual)

Groups and cohorts

  • Case
  • Control
05

Study locations

10 sites
  • Barrow Neurological Institute
    Phoenix, Arizona 85013, United States
  • Stanford University
    Stanford, California 94305, United States
  • The Rocky Mountain MS Center at Anschutz Medical Campus at UC Denver
    Aurora, Colorado 80045, United States
  • Shepherd Center
    Atlanta, Georgia 30309, United States
  • Johns Hopkins
    Baltimore, Maryland 21287, United States
  • Beth Israel Deaconess
    Boston, Massachusetts 02215, United States
  • University of Massachusetts Medical School
    Worcester, Massachusetts 01605, United States
  • Multiple Sclerosis Research Center of New York
    New York, New York 10019, United States
  • The Ohio State University
    Columbus, Ohio 43210, United States
  • University of Texas Southwestern Medical Center at Dallas
    Dallas, Texas 76051, United States
06

References and documents

07

Registry details

Key details

Study ID
NCT00445367
Lead sponsor
Accelerated Cure Project for Multiple Sclerosis
Responsible party
Sponsor
First posted
Mar 9, 2007
Start date
May 2006
Primary completion
Oct 2030 (estimated)
Completion
Oct 2036 (estimated)
Last update
Oct 2, 2025

Study contacts

Benjamin Greenberg, M.D., M.H.S.
principal investigator · University of Texas

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Multiple Sclerosis→

Other studies from this sponsor

Accelerated Cure Project for Multiple Sclerosis

Start the discussion